Key result
Vericiguat, a soluble guanylate cyclase stimulator, has shown add-on therapy efficacy by reducing morbidity and mortality in patients with worsening chronic heart failure.
Why the study?
Significant morbidity and mortality in patients with heart failure, notably in the most advanced forms, justify the need for novel therapeutic options.
Does vericiguat reduce morbidity and mortality in patients with worsening chronic heart failure?
Does vericiguat reduce morbidity and mortality in patients with worsening chronic heart failure?
Vericiguat acts as a novel sGC stimulator that complements current pharmacotherapy by reducing morbidity and mortality in patients with worsening chronic heart failure.
Answers are grounded in this paper and cite their sources.
Supports vericiguat add-on in worsening HF; leaves open need for confirmatory randomized trials.
INTRODUCTION: The significant morbidity and mortality in patients with heart failure (HF), notably in the most advanced forms of the disease, justify the need for novel therapeutic options. In the last year, the soluble guanylate cyclase (sGC) stimulator, vericiguat, has drawn the attention of the medical community following the report of reduced clinical outcomes in patients with worsening chronic HF (WCHF). AREAS COVERED: The authors review the available data on the mechanism of action of vericiguat (cyclic guanosine monophosphate (cGMP) pathway), its clinical development program, its role in HF management, and its future positioning in the therapeutic recommendations. EXPERT OPINION: cGMP deficiency has deleterious effects on the heart and contributes to the progression of HF. Different molecules, including nitric oxide (NO) donors, phosphodiesterase inhibitors, and natriuretic peptides analogues, target the NO-sCG-cGMP pathway but have yielded conflicting results in HF patients. Vericiguat acts as a sGC stimulator thus targeting the NO-sGC-cGMP pathway by a different mechanism that complements the current pharmacotherapy for HF. Vericiguat has shown an additional statistical add-on therapy efficacy by reducing morbi-mortality in patients with WCHF. A better evaluation of HF severity might be an important determinant to guide the use of vericiguat among the available therapies.
No takes yet. Share an insight, caveat, or question.
Hulot et al. (2021) conducted a review in Worsening chronic heart failure. Vericiguat was evaluated. Vericiguat, a soluble guanylate cyclase stimulator, has shown add-on therapy efficacy by reducing morbidity and mortality in patients with worsening chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: